首页 > 市场调查报告书 > 製药

癌症分子标靶治疗学

市场调查报告书

商品编码

1833290

CD40标靶治疗药的全球市场:临床试验，治疗方法，专利技术平台，市场机会相关洞察(2026年)

Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

出版日期: 2025年10月01日 | 出版商:

KuicK Research | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球 CD40 标靶治疗市场 - 临床试验、治疗方法、专有技术平台及市场机会洞察（2026 年）报告结果与亮点

首个 CD40 标靶治疗预计将于 2027 年获批
临床试验中的 CD40 标靶治疗：超过 35 种疗法
按公司、国家、适应症和治疗阶段划分的 CD40 标靶治疗临床试验洞察
按公司划分的 CD40 标靶治疗专有技术
按地区划分的 CD40 标靶治疗市场趋势分析
竞争格局

对 CD40 标靶治疗的需求以及本报告的意义

CD40标靶疗法是免疫疗法领域的一项重大突破，为自体免疫疾病、癌症甚至某些感染性疾病的治疗提供了新的潜力。与通常广泛抑制免疫系统的传统疗法不同，CD40标靶疗法选择性地靶向免疫细胞上的CD40受体，从而特异性地调节免疫反应。这种方法可以调节免疫系统，而不会产生传统疗法的普遍免疫抑制和副作用，从而有望带来更好、更安全的治疗方案。由于临床试验结果持续向好，CD40标靶疗法正被用于治疗狼疮性肾炎、多发性硬化症和癌症等自体免疫疾病，这有可能为这些复杂疾病的治疗带来革命性的变革。

本报告对新兴的CD40标靶疗法市场进行了深入分析，旨在让利害关係人了解最新进展和未来趋势。报告对目前的临床试验、领先的製药公司以及最有前景的候选药物研发管线提供了独特的见解。此外，本报告也探讨了可能推动开发更具针对性和有效性的CD40标靶疗法的技术创新和合作措施。本报告简要概述了市场的现状和未来潜力，为投资者、研发专业人员和医疗保健专业人员提供了解这一快速发展市场的关键资讯。

报告中涵盖的临床试验见解

鑑于临床试验对于CD40标靶疗法的开发至关重要，本报告深入探讨了正在进行和即将进行的临床试验，这些试验将决定这些疗法的未来发展。 1期临床试验已显示出良好的结果，一些针对自体免疫疾病的疗法已进入3期试验。这些临床试验不仅开发了CD40标靶药物的治疗潜力，还确定了哪些候选药物最有可能在更大的市场中取得成功。

本报告也简要介绍了全球市场对这些疗法日益增长的需求。虽然美国在CD40标靶研究方面处于领先地位，但中国、澳洲和欧洲部分地区等其他地区的临床试验规模也不断扩大。这种地理分布的不断扩大反映出，CD40标靶疗法目前正在全球范围内得到探索，并在各个医疗保健市场中带来了新的机会。

参与CD40标靶疗法研发的顶尖公司

除了尖端生技公司外，许多顶尖製药公司也在引领CD40标靶疗法的研发。这些公司正在突破常规思维，创新疗法，这些疗法可能会彻底改变自体免疫疾病、癌症和其他疾病的治疗。一些候选药物已进入后期临床试验阶段，而另一些则处于早期开发阶段，并已显示出良好的临床前数据。

本报告概述了在CD40标靶疗法研究方面处于领先地位的行业领袖的努力。这些公司正在利用先进技术和科学创新来提高治疗的安全性和有效性。製药、生物技术和学术界之间的联盟与合作也正在加速开发进程，并建立合作关係，这将在不久的将来带来突破。

技术平台、合作伙伴关係和协定

本报告的很大一部分内容致力于介绍能够设计更有效、更有针对性的CD40疗法的技术进步。各公司正在应用新的平台来提高CD40标靶的特异性，最大限度地提高治疗效果，同时减少副作用。一个例子是结合靶向树突状细胞的单株抗体和抗原，有可能更精准、更持久地增强免疫反应。

製药、生物技术和学术界之间的合作也正在加快该领域的创新步伐。合作研究对于克服与CD40标靶疗法开发相关的复杂问题（例如优化递送机制和长期安全性问题）至关重要。本报告介绍了几个合作研究项目，并重点介绍了该领域的一些有希望的进展。

First CD40 Targeted Therapy Approval Expected By 2027
CD40 Targeted Therapies In Clinical Trials: > 35 Therapies
CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
CD40 Targeted Therapies Proprietary Technologies By Company
CD40 Targeted Therapy Market Trend Analysis By Region
Competitive Landscape

Need For CD40 Targeted Therapies & Why This Report?

CD40 targeting therapies are now emerging as a major breakthrough in immunotherapy, holding new promise for autoimmune disease, cancer, and even for certain infectious diseases. In contrast to conventional treatments, which generally dampen the immune system in a broad way, CD40 targeting therapies seek to modulate immune reactions specifically by selectively targeting the CD40 receptor on immune cells. This method may result in better and safer therapies because it can modulate the immune system without leading to the generalized immune suppression and side effects of traditional treatments. With continued encouraging findings from clinical trials, CD40 targeted therapy is being investigated for autoimmune diseases such as lupus nephritis, multiple sclerosis, and cancer, marking a groundbreaking change in the treatment of these intricate illnesses.

The report presents a detailed analysis of the emerging CD40 targeted therapy market, aimed at keeping stakeholders up to date with the recent advancements and upcoming trends. The report provides unique insights into current clinical trials, major pharmaceutical companies, and the most promising pipeline drug candidates. Additionally, the report explores technological innovations and collaborative initiatives that are driving the development of more targeted and efficacious CD40 targeting therapies. With both a snapshot of the present state of the market as well as its future potential, the report arms investors, researchers, and healthcare professionals alike with critical information to make sense of this fast developing space.

Clinical Trials Insight Covered In Report

With clinical trials remaining central to the development of CD40 targeted therapies, this report looks closely at the ongoing and upcoming trials that are defining the future of the therapies. Phase trials have already demonstrated encouraging results, with certain therapies progressing to Phase 3 trials for autoimmune conditions. Such trials serve not only to develop the therapeutic potential of CD40 targeting agents but also to determine which drug candidates have the greatest likelihood of success in the larger market.

The report also briefly addresses the increasing demand for such therapies in global markets. As great a lead as the US has taken with CD40 targeted research, there has been a growing presence of trials in other areas, including China, Australia, and parts of Europe. The fact that this geographical presence is broadening reflects the fact that CD40 targeted therapies are now being considered all over the world, with new opportunities in different healthcare markets.

Top Companies Involved In R&D Of CD40 Targeting Therapy

A number of top pharmaceutical companies, in addition to cutting edge biotech companies, are leading research and development in CD40 targeted therapy. These corporations are breaking the mold, innovating new therapies that have the potential to profoundly transform the treatment of autoimmune diseases, cancers, and more. Some candidates are in later clinical stages, while others are still in early development but are indicating encouraging preclinical data.

This report highlights the efforts of leading players in the industry that are pioneering the research in CD40 targeting therapies. These players are making use of advanced technologies and scientific innovations to enhance the safety and efficacy of the therapies. Alliances and collaboration between pharmaceutical firms, biotech companies, and academia are also speeding up the process of development, establishing a collaborative system that will culminate in breakthroughs in the near term.

Technology Platforms, Partnerships & Agreements

Much of the report is dedicated to the technological advancements that are making it possible to design more potent and targeted CD40 treatments. Novel platforms are being applied by companies to increase the specificity of CD40 targeting, reducing side effects while maximizing therapeutic effect. The case in point is incorporating monoclonal antibodies and antigens to target dendritic cells, which might increase the immune response in a more precise and long lasting fashion.

Pharma, biotech, and academic collaborations are also speeding up the innovation rate in the field. The collaborations are needed to overcome the complexity issues related to the development of CD40 targeted therapy, including optimization of the delivery mechanisms as well as long term safety issues. The report highlights some of the collaborations and alludes to the promising advances being made in the field.

1. Introduction To CD40 Targeted Therapies

1.1 Overview
1.2 Considering CD40 As Drug Target Over Other CD Markers
1.3 History & Evolution Of CD40 Targeting Therapies

2. CD40 Targeted Therapies - Mechanism Of Action

2.1 Agonist Mediated Activation Of CD40 Signaling
2.2 Antagonist Mediated Inhibition Of CD40 Signaling

3. CD40 Targeted Therapeutic Approaches

3.1 Antibody Formats
3.2 Fusion Proteins
3.3 Peptides
3.4 Nucleic Acids

4. CD40 Targeted Therapy Research & Development Trends By Indication

4.1 Cancer
4.2 Neurological Diseases
4.3 Autoimmune & Inflammatory Disorders
4.4 Transplant Rejection
4.5 Microbial Infections

5. CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
5.6 Phase III

6. Global CD40 Targeted Therapy Market Outlook

6.1 Current Market Trends & Developments
6.2 Future Market Opportunities

7. CD40 Targeted Therapy Market Trend Analysis By Region

7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 Australia

8. CD40 Targeted Therapies - Proprietary Technologies By Company

9. Global CD40 Targeted Therapy Market Dynamics

9.1 Drivers & Opportunities
9.2 Challenges & Restraints

10. Competitive Landscape

10.1 Alligator Bioscience
10.2 Amgen
10.3 Biogen
10.4 BioNTech
10.5 Eledon Pharmaceuticals
10.6 EnnoDC
10.7 Genmab
10.8 Innovent Bio
10.9 Novartis
10.10 Sanofi
10.11 Tonix Pharmaceuticals
10.12 UCB

简介目录图表

List of Figures

Figure 1-1: CD40 - Salient Features
Figure 1-2: CD40 Targeted Therapy Landscape - Major Milestones
Figure 2-1: CD40 Agonists - Mechanism Of Action
Figure 2-2: CD40 Antagonists - Mechanism Of Action
Figure 3-1: Prominent Antibody Formats For Targeting CD40
Figure 3-2: CD40 Fusion Protein Types & Properties
Figure 3-3: CD40 Fusion Proteins - Advantages & Challenges
Figure 3-4: Advantages vs. Challenges Of Peptides For CD40 Targeting
Figure 3-5: siRNA Delivery Mechanism & Effect On Immune Cells
Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study - Initiation & Completion Year
Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study - Initiation & Completion Year
Figure 4-3: 2141-V11 Phase 1 (NCT06455605) Study - Initiation & Completion Year
Figure 4-4: 2141-V11 Phase 1/2 (NCT05734560) Study - Initiation & Completion Year
Figure 4-5: 2141-V11 Phase 1/2 (NCT05126472) Study - Initiation & Completion Year
Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study - Initiation & Completion Year
Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study - Initiation & Completion Year
Figure 4-8: FREXALT 3 (NCT06141473) Study - Initiation & Completion Year
Figure 4-9: PHOENYCS FLY Phase 3 (NCT06617325) Study - Initiation & Completion Year
Figure 4-10: SL0046 Phase 3 (NCT04976322) Study - Initiation & Completion Year
Figure 4-11: HZNP-DAZ-301 Phase 3 (NCT06104124) Study - Initiation & Completion Year
Figure 4-12: HZNP-DAZ-303 Phase 3 (NCT06245408) Study - Initiation & Completion Year
Figure 4-13: VIBRANT Phase 2 (NCT05201469) Study - Initiation & Completion Year
Figure 4-14: FABULINUS Phase 2 (NCT06111586) Study - Initiation & Completion Year
Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study - Initiation & Completion Year
Figure 4-16: IRB23-1367 Phase 1/2 (NCT06111586) Study - Initiation & Completion Year
Figure 4-17: AT-1501-K102 Phase 1 (NCT05027906) Study - Initiation & Completion Year
Figure 4-18: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study - Initiation & Completion Year
Figure 4-19: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study - Initiation & Completion Year
Figure 4-20: ANRS VRI06 Phase 1 (NCT04842682) Study - Initiation & Completion Year
Figure 4-21: HVTN 318 Phase 1 (NCT06665646) Study - Initiation & Completion Year
Figure 4-22: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study - Initiation & Completion Year
Figure 4-23: HPVDCVax Phase 1/2 (NCT06007092) Study - Initiation & Completion Year
Figure 5-1: Global - CD40 Targeted Therapies In Clinical Trials, 2025 -2026
Figure 6-1: CD40 Targeted Therapy - Future Opportunities
Figure 8-1: Alligator Bioscience - FIND technology
Figure 8-2: Alligator Bioscience - Neo-X-Prime
Figure 8-3: Aprilbio - SAFA Antibody APB-A1
Figure 8-4: Genmab - DuoBody
Figure 8-5: Harbour BioMed - Harbour Mice
Figure 8-6: Harbour BioMed - HCAb
Figure 8-7: H2L2 & HCAb Platforms - Features
Figure 8-8: Harbour BioMed - HBICE
Figure 8-9: Kyowa Kirin - REGULGENT
Figure 8-10: ADAC Technology Platform - Features
Figure 8-11: Strike Pharma - ADAC Technology Platform
Figure 8-12: Strike Pharma - ADAC Molecule
Figure 9-1: CD40 Targeted Therapy Market - Drivers & Opportunities
Figure 9-2: CD40 Targeted Therapy Market - Challenges & Restraints

List of Tables

Table 3-1: Comparison Of siRNA vs. Anti-CD40 Antibody Therapy
Table 5-1: CD40 Targeted Therapies In Research Stage, 2025 - 2026
Table 5-2: CD40 Targeted Therapies In Preclinical Stage, 2025 - 2026
Table 5-3: CD40 Targeted Therapies In Phase I, 2025 - 2026
Table 5-4: CD40 Targeted Therapies In Phase I/II, 2025 - 2026
Table 5-5: CD40 Targeted Therapies In Phase II, 2025 - 2026
Table 5-6: CD40 Targeted Therapies In Phase III, 2025 - 2026
Table 6-1: CD40 Targeted Therapies In Phase III Clinical Trials

02-2729-4219

+886-2-2729-4219

License/价格

CD40标靶治疗药的全球市场:临床试验，治疗方法，专利技术平台，市场机会相关洞察(2026年)

Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

目录

第1章 CD40标靶治疗的简介

第2章 CD40标靶治疗- 作用机制

第3章 CD40标靶治疗方法

第4章 CD40标靶治疗的研究开发趋势，各适应症

第5章 CD40标靶治疗的临床试验:企业，国家，适应症，各相

第6章全球CD40标靶治疗市场展望

第7章 CD40标靶治疗市场趋势分析(各地区)

第8章 CD40标靶治疗- 各企业专利技术

第9章全球CD40标靶治疗市场动态

第10章竞争情形